Skip to content
Peptide research

AHK-Cu

Also known as Copper Tripeptide-3
Category
Skin & Cosmetic
Administration routes
Topical
Regulatory status
Cosmetic ingredient

AHK-Cu is a copper-binding peptide marketed for hair regrowth and skin support, said to activate the dermal papilla and support collagen. The evidence is almost entirely cell-culture and mechanism work; there are no controlled human trials, so the human case is weak. Safety data is thin, and it is contraindicated in Wilson disease, Menkes disease, and copper allergy. It is not an approved drug; it is sold in cosmetics subject to FDA cosmetic requirements and as unregulated products sold online.

This is educational content compiled from published research, not medical advice. Always consult a licensed healthcare provider before using any peptide. Medical disclaimer

Compiled from published research indexed through March 2026.

Overview

AHK-Cu (Copper Tripeptide-3) is a synthetic copper peptide made of three amino acids (alanine, histidine, and lysine) bound to a copper ion. Unlike its more famous cousin GHK-Cu, AHK-Cu was specifically engineered for hair and scalp applications. Laboratory experiments found increased isolated follicle elongation and dermal papilla cell proliferation, with changes in apoptosis-related proteins. The decrease in apoptotic cells was not statistically significant, and the study did not establish scalp blood-vessel formation or clinical hair regrowth.

How it works in the body

Binds copper and delivers it to hair follicle cells, where it stimulates the dermal papilla — the signaling center that controls hair growth. It activates genes involved in hair growth while suppressing those that cause follicle shrinkage.

Research overview

AHK-Cu works by stimulating the dermal papilla cells at the base of hair follicles, promoting hair follicle elongation, boosting blood vessel growth factor (VEGF) production, and tipping the balance in follicle cells toward survival rather than programmed cell death. The foundational 2007 study from Seoul National University showed it effectively stimulated human hair follicle growth in lab settings at extremely low concentrations (picomolar to nanomolar range). The broader copper peptide family, including GHK-Cu which has been studied since the 1970s, is known to stimulate collagen and elastin production and support tissue remodeling. However, AHK-Cu research is considerably more limited than GHK-Cu, with only a handful of published studies focused specifically on this variant. Most evidence is from lab and cell culture studies rather than clinical trials in humans.

Who researches AHK-Cu?

Commonly researched by

  • People exploring tissue repair and injury recovery

    Studied for effects on wound healing, tendon/ligament repair, or recovery from injury.

  • People researching skin health and rejuvenation

    Studied for collagen synthesis, skin repair, or anti-aging skin effects.

  • People researching hair restoration options

    Explored for effects on hair follicle stimulation or hair regrowth.

  • People researching inflammation management

    Studied for anti-inflammatory effects across various conditions.

Important considerations for

  • Those who are pregnant or breastfeeding

    Absolute

    No human reproductive safety data exists for this peptide. Effects on fetal development are unknown.

  • Anyone under 18

    Absolute

    No pediatric safety data. Not recommended for use in minors.

  • Those with Known hypersensitivity

    Absolute

    Discontinue immediately if allergic reaction occurs (rash, swelling, difficulty breathing).

Safety & interactions

General cautions

  • Pregnancy or breastfeeding

    Absolute

    No human reproductive safety data exists for this peptide. Effects on fetal development are unknown.

  • Children under 18

    Absolute

    No pediatric safety data. Not recommended for use in minors.

  • Known hypersensitivity

    Absolute

    Discontinue immediately if allergic reaction occurs (rash, swelling, difficulty breathing).

How to read the ratings

Benefits
= confidence in the evidence: High · Medium · Low · Speculative (High requires human randomized trials for that specific benefit)
Risks
= level of concern: High · Moderate · Low · Theoretical
Interactions
= direction with this peptide: Protective / Synergistic · Caution · Neutral

Risk summary(12)

Rated by level of concern

  • Limited long-term safety data — most studies are short-duration in vitro experiments

    High

    PMID 17703734; no registered or published AHK-Cu human trials identified

  • Contraindicated in Wilson disease (copper metabolism disorder) and Menkes disease

    Moderate

    Established Wilson disease management; copper-histidine is standard Menkes therapy

  • Contraindicated in individuals with copper allergies

    Moderate

    Fage et al., copper hypersensitivity review, Contact Dermatitis 2014

  • Insufficient safety data for use during pregnancy and breastfeeding — avoid as precaution

    Moderate

    Absence of published reproductive toxicology for AHK-Cu

  • Local skin irritation (redness, itching) at application site — generally mild and transient

    Low

    General topical copper-peptide tolerability; no AHK-Cu trial data

  • Should not be applied to broken, infected, or actively inflamed skin

    Low

    General topical dermatology principle

  • Short in vivo half-life (<30 minutes in plasma) limits systemic bioavailability

    Theoretical

    No AHK-Cu PK study located; the <30-minute figure is unverified

  • Rapid enzymatic degradation by proteases may reduce efficacy without proper formulation

    Low

    Rationale for palmitoylated AHK derivatives; no direct AHK-Cu stability study located

  • Potential for allergic/hypersensitivity reactions (rare)

    Low

    Copper contact-allergy literature generally (Fage et al., Contact Dermatitis 2014); no AHK-Cu case reports

  • Potential copper toxicity if combined with oral copper supplements — monitor total copper intake

    Theoretical

    No documented case; mechanistic inference

  • Temporary increased hair shedding in first 4-6 weeks of use (adjustment period)

    Theoretical

    Extrapolated from minoxidil; no AHK-Cu source

  • Metallic taste or nausea reported rarely — discontinue if persistent

    Theoretical

    No primary source located

Interaction summary(8)

Rated by direction with this peptide

  • Copper chelation therapy for Wilson disease (penicillamine, trientine, bis-choline tetrathiomolybdate)

    CautionModerate

    Applying an exogenous copper-delivering peptide runs counter to the therapeutic goal of copper depletion and should be avoided by anyone on de-coppering therapy. The absolute copper delivered topically is small and no clinical case of interference is documented, but the avoidance is standard practice in this population.

    Established Wilson disease management principle; no AHK-Cu-specific interaction study

  • Oral copper supplements and copper-containing multivitamins

    CautionTheoretical

    Total copper intake is additive in principle, though the copper delivered by topical AHK-Cu at active concentrations is negligible next to dietary and supplemental sources, so this matters mainly in copper-handling disorders.

    Mechanistic; no documented case of additive copper toxicity from topical copper peptides

  • High-dose zinc supplementation

    CautionTheoretical

    Chronic high-dose zinc induces intestinal metallothionein and antagonizes copper absorption — a real systemic copper interaction, but one unlikely to meaningfully alter a topically applied copper peptide.

    Established zinc-copper antagonism; no AHK-Cu-specific data

  • Topical minoxidil

    SynergisticTheoretical

    Mechanisms are complementary and non-overlapping — minoxidil is a potassium-channel opener and vasodilator, while AHK-Cu acts on dermal papilla proliferation and VEGF in vitro — but no combination study in humans or animals exists, so synergy is a hypothesis rather than a finding.

    Mechanistic inference; no combination trial identified

  • Finasteride / dutasteride (5-alpha-reductase inhibitors)

    SynergisticTheoretical

    Distinct pathways — systemic DHT suppression versus local dermal papilla signaling — with no known pharmacokinetic or pharmacodynamic conflict, but the combination has never been formally tested and the TGF-beta1 rationale sometimes offered for it is unsourced for AHK-Cu.

    Mechanistic inference; no combination trial identified

  • Topical L-ascorbic acid (vitamin C serums) applied at the same time

    CautionLow

    Low-pH ascorbic acid can reduce and destabilize the copper-peptide complex, and copper catalyzes ascorbate oxidation, so co-application in the same layer risks mutual degradation — separating applications is the usual mitigation. This is a formulation-stability issue, not a toxicity one.

    Redox/formulation chemistry applied to copper peptides generally

  • Topical retinoids and alpha/beta hydroxy acids

    CautionLow

    Cumulative barrier disruption and additive irritation, plus low-pH acid vehicles that may destabilize the copper-peptide complex; a concern about layering topicals rather than a pharmacologic interaction.

    General topical dermatology; no AHK-Cu-specific study

  • Topical corticosteroids on the same skin area

    NeutralTheoretical

    No known chemical interaction, though corticosteroid suppression of fibroblast collagen synthesis would be expected to blunt any AHK-Cu ECM effect if used concurrently on the same site.

    Mechanistic inference; no interaction study

Known risks(12)

  • Local skin irritation (redness, itching) at application site — generally mild and transient

  • Temporary increased hair shedding in first 4-6 weeks of use (adjustment period)

  • Potential copper toxicity if combined with oral copper supplements — monitor total copper intake

  • Contraindicated in Wilson disease (copper metabolism disorder) and Menkes disease

  • Contraindicated in individuals with copper allergies

  • Should not be applied to broken, infected, or actively inflamed skin

  • Insufficient safety data for use during pregnancy and breastfeeding — avoid as precaution

  • Short in vivo half-life (<30 minutes in plasma) limits systemic bioavailability

  • Rapid enzymatic degradation by proteases may reduce efficacy without proper formulation

  • Limited long-term safety data — most studies are short-duration in vitro experiments

  • Metallic taste or nausea reported rarely — discontinue if persistent

  • Potential for allergic/hypersensitivity reactions (rare)

Drug interactions(8)

  • Minoxidil

    AHK-Cu and minoxidil may have complementary mechanisms for hair growth. Minoxidil works primarily as a vasodilator while AHK-Cu targets dermal papilla cell survival and proliferation. Can be used together.

  • Finasteride / Dutasteride

    AHK-Cu reduces TGF-beta1 signaling while 5-alpha-reductase inhibitors block DHT production. Complementary anti-hair-loss mechanisms. Can be used together (topical + oral).

  • GHK-Cu

    Complementary copper peptides. GHK-Cu provides broader skin rejuvenation while AHK-Cu targets follicular biology. No contraindications to combined use.

  • Hyaluronic Acid

    Compatible for combined topical use. Hyaluronic acid provides hydration support while AHK-Cu stimulates regeneration.

  • Vitamin C (L-Ascorbic Acid)

    High-dose vitamin C at low pH can destabilize copper peptide complexes and potentially reduce efficacy. Apply at different times or use buffered vitamin C derivatives.

  • AHA/BHA Acids (Glycolic, Salicylic)

    Low-pH chemical exfoliants may destabilize AHK-Cu. Separate application times by several hours or use on alternating days.

  • Retinoids (Tretinoin, Retinol)

    Potential for increased irritation when combining copper peptides with retinoids. Stagger application (e.g., retinoid at night, AHK-Cu in morning) or use on alternating days.

  • Oral Copper Supplements

    Risk of copper toxicity when combining topical copper peptides with oral copper supplementation. Monitor total copper intake. Hepatotoxicity possible with copper overload.

Research & benefits

Evidence base

Evidence Level
Preclinical
Total Studies
5
Human Studies
0

The primary evidence comes from the Pyo et al. (2007) study at Seoul National University, which demonstrated AHK-Cu stimulates hair follicle elongation ex vivo and DPC proliferation in vitro using human tissue. The study employed rigorous methods including flow cytometry and Western blotting. Additional supportive evidence comes from the broader copper peptide literature, particularly the extensive GHK-Cu research base. The tripeptide class has been validated in multiple wound healing and skin regeneration studies.

Researched for(12)

Rated by confidence in the evidence

  • Stimulates hair follicle elongation and extends the anagen (active growth) phase

    Speculative

    Single ex vivo human follicle study measured elongation; anagen-phase extension is inferred, not directly shown.

    PMID 17703734 (elongation only; anagen extension is inference)

  • Promotes dermal papilla cell proliferation at picomolar to nanomolar concentrations

    Speculative

    Dose-dependent effect shown in cultured human dermal papilla cells in one 2007 study, never replicated.

    PMID 17703734

  • Anti-apoptotic effects: increases Bcl-2/Bax ratio, reduces cleaved caspase-3 and PARP

    Low

    Shown in vitro/ex vivo: AHK-Cu raised Bcl-2/Bax and lowered cleaved caspase-3, PARP in human dermal papilla cells.

    Pyo HK et al., Arch Pharm Res 2007;30(7):834-839, PMID 17703734 (human dermal papilla cells and ex vivo hair follicles, 10^-9 M AHK-Cu; Bcl-2 up/Bax down p<0.05; cleaved caspase-3 down 42.7% p<0.05; PARP cleavage fragments down 77.5% p<0.05)

  • Upregulates vascular endothelial growth factor (VEGF) for improved blood supply to follicles and skin

    Speculative

    VEGF increase shown in cultured dermal papilla cells; improved blood supply is an unproven inference.

    PMID 17703734 (VEGF in dermal papilla cells); vascular benefit is inference

  • Reduces TGF-beta1 signaling, which may counteract DHT-mediated follicle miniaturization

    Speculative

    No direct AHK-Cu evidence; DHT-miniaturization link is a hypothesis from the GHK-Cu peptide class.

    Mechanistic hypothesis and GHK-Cu class extrapolation; no verified AHK-Cu source for TGF-beta1

  • Stimulates collagen type I expression in dermal fibroblasts

    Speculative

    No AHK-Cu fibroblast data exists; based on GHK-Cu class evidence and copper's lysyl oxidase role.

    Class extrapolation from GHK-Cu plus copper/lysyl-oxidase mechanism; no AHK-Cu primary source located

  • Promotes elastin and glycosaminoglycan (including hyaluronic acid) synthesis

    Speculative

    No AHK-Cu-specific studies exist; extrapolated from GHK-Cu data and copper's elastin cofactor role.

    Class extrapolation from GHK-Cu; no AHK-Cu primary source located

  • Supports extracellular matrix remodeling and tissue repair

    Speculative

    Plausible from dermal papilla cell data, but no AHK-Cu wound-healing or tissue-repair study exists.

    Mechanistic inference and GHK-Cu extrapolation; no AHK-Cu primary source located

  • Enhances angiogenesis by stimulating endothelial cell migration to wound sites

    Speculative

    Inferred from reported VEGF upregulation; endothelial migration itself has never been tested for AHK-Cu.

    Mechanism-only for AHK-Cu

  • Antioxidant properties through copper-mediated enzymatic reactions

    Speculative

    Mechanism-only, based on copper's role as a cofactor for antioxidant enzymes, with no AHK-Cu data.

    Mechanism-only; no AHK-Cu primary source located

  • Anti-inflammatory effects that benefit stressed or sensitive skin

    Speculative

    No AHK-Cu inflammation studies exist; claim is borrowed from the GHK-Cu peptide literature.

    Mechanism-only; no AHK-Cu primary source located

  • Supports skin barrier function and hydration retention

    Speculative

    No published AHK-Cu data on skin barrier or hydration measures; based on cosmetic marketing claims.

    No primary source located

Benefits(12)

  • Stimulates hair follicle elongation and extends the anagen (active growth) phase

  • Promotes dermal papilla cell proliferation at picomolar to nanomolar concentrations

  • Anti-apoptotic effects: increases Bcl-2/Bax ratio, reduces cleaved caspase-3 and PARP

  • Upregulates vascular endothelial growth factor (VEGF) for improved blood supply to follicles and skin

  • Reduces TGF-beta1 signaling, which may counteract DHT-mediated follicle miniaturization

  • Stimulates collagen type I expression in dermal fibroblasts

  • Promotes elastin and glycosaminoglycan (including hyaluronic acid) synthesis

  • Supports extracellular matrix remodeling and tissue repair

  • Enhances angiogenesis by stimulating endothelial cell migration to wound sites

  • Antioxidant properties through copper-mediated enzymatic reactions

  • Anti-inflammatory effects that benefit stressed or sensitive skin

  • Supports skin barrier function and hydration retention

Key studies(4)

  1. Pyo HK, Yoo HG, Won CH, Lee SH, Kang YJ, Eun HC, Cho KH, Kim KH

    Archives of Pharmacal Research

    2007

    AHK-Cu at 10^-12 to 10^-9 M stimulated hair follicle elongation ex vivo and dermal papilla cell proliferation in vitro. Reduced apoptosis markers (caspase-3, PARP) and increased Bcl-2/Bax ratio. Conducted at Seoul National University, Department of Dermatology.

  2. Pickart L, Margolina A

    International Journal of Molecular Sciences

    2018

    Comprehensive review of GHK-Cu showing it affects ~31.2% of human genes. Demonstrated 70% collagen production improvement, stimulated blood vessel and nerve outgrowth, and showed protective actions including anti-inflammatory, antioxidant, and anti-cancer properties. Provides mechanistic context for copper peptide class including AHK-Cu.

  3. Pickart L, Vasquez-Soltero JM, Margolina A

    BioMed Research International

    2015

    Detailed review of GHK as a modulator of cellular pathways in skin regeneration. Demonstrated collagen, elastin, and glycosaminoglycan synthesis stimulation. Provides foundational copper peptide science applicable to AHK-Cu mechanisms.

  4. Adnan SB, Maarof M, Fauzi MHB, Fadilah NIM

    International Journal of Medical Sciences

    2025

    Comprehensive review confirming tripeptides regulate cell migration, proliferation, differentiation, inflammation, angiogenesis, and ECM remodeling. Noted critical barriers: short in vivo half-life (<30 min), poor skin penetration, rapid enzymatic degradation. Tripeptides offer low-cost synthesis, low immunogenicity, and high biocompatibility.

Regulation & availability

Why researchers look at it

A 2007 Seoul National University study showed this GHK-Cu derivative promoted human hair follicle growth at remarkably low concentrations (picomolar range) while boosting VEGF production and tipping follicle cells toward survival. Unlike its well-known cousin GHK-Cu, AHK-Cu was specifically engineered for hair loss. No large-scale human trials exist yet, but if future studies confirm its targeted efficacy at such low doses, it could carve out a distinct niche in peptide-based hair restoration.

Estimated cost
$20-60/mo in OTC hair/skin serums
FDA status
Not FDA-approved as a drug or biologic. AHK-Cu is classified as a cosmetic ingredient when used in topical skincare and haircare products. It is not regulated as a pharmaceutical. No FDA New Drug Application (NDA) or Investigational New Drug (IND) applications are publicly listed for AHK-Cu. The peptide falls under cosmetic regulations when marketed for appearance-related claims (e.g., hair appearance, skin texture) rather than therapeutic claims. No FDA monograph exists for this compound.
WADA status
AHK-Cu is not named in the 2026 WADA List. This does not establish clearance: S0 and class-based provisions may cover unnamed substances. Obtain a compound-specific determination from the relevant anti-doping organization.
Prescribability
AHK-Cu is not an FDA-approved drug and is not prescribed by physicians. It is sold as a topical cosmetic raw material or in finished skincare/haircare formulations.
Availability
Sold as raw powder (99% purity), liposomal solutions (e.g., 10% AHK-Cu liposome), and in finished haircare/skincare formulations. Not available as a pharmaceutical product. Topical formulations are the primary delivery method; injectable forms are not commercially available for this peptide. CAS number: 682809-81-0.

International status

  • EU

    Not approved

  • US

    Not FDA-approved as a drug. Products making only cosmetic appearance claims are subject to cosmetic requirements; hair-regrowth claims trigger drug requirements.

  • Worldwide

    No regulatory approval in any jurisdiction

Regulatory timeline(6)

  1. 2007
    Foundational study by Pyo et al. at Seoul National University published in Archives of Pharmacal Research, reporting AHK-Cu effects on hair follicle elongation and DPC proliferation in vitro (PMID: 17703734)
  2. 2015
    Pickart et al. published comprehensive review of GHK peptide in skin regeneration (PMC4508379), providing broader mechanistic context for copper peptide class
  3. 2018
    Pickart & Margolina published updated review of GHK-Cu regenerative and protective actions with gene data (PMC6073405), further validating copper peptide mechanisms
  4. 2020
    AHK-Cu gains commercial traction in cosmetic and haircare markets. CAS 682809-81-0 registered.
  5. 2025
    Adnan et al. published comprehensive tripeptide review in International Journal of Medical Sciences (DOI: 10.7150/ijms.118118), validating tripeptide mechanisms in wound healing and skin regeneration
  6. 2026
    AHK-Cu remains classified as a cosmetic ingredient. No FDA drug approval process initiated. Growing presence in consumer haircare and anti-aging formulations. Research base expanding but still limited compared to GHK-Cu.

Sources & FAQs

Research sources(5)

Frequently asked questions(5)

What is the difference between AHK-Cu and GHK-Cu?

GHK-Cu (Glycine-Histidine-Lysine copper) is a naturally occurring peptide found in human plasma that declines with age. It has been studied since the 1970s and affects approximately 4,000 human genes, making it broadly useful for skin rejuvenation, wound healing, and anti-aging. AHK-Cu (Alanine-Histidine-Lysine copper) is a synthetic analog where glycine is replaced with alanine. It was specifically engineered for hair follicle applications and has a more targeted research base focused on dermal papilla cell stimulation and hair growth. GHK-Cu is considered the gold standard for overall skin health, while AHK-Cu is preferred for hair-specific applications.

How long does AHK-Cu take to show results for hair growth?

The cited laboratory study cannot establish when visible hair growth or initial shedding might occur in people.

Is AHK-Cu safe?

AHK-Cu has a favorable safety profile in topical applications based on available data. Common side effects are mild and include local redness, itching, and temporary increased shedding. It is contraindicated in individuals with copper allergies, Wilson disease, or Menkes disease. It should not be applied to broken or infected skin. Caution is advised during pregnancy and breastfeeding due to lack of safety data. No serious adverse events have been reported in the literature.

How do AHK-Cu and GHK-Cu differ?

GHK-Cu provides broader skin rejuvenation and anti-aging benefits, while AHK-Cu targets hair follicle health specifically. Some formulations contain both peptides, and no contraindications to using them together are known.

At what concentration is AHK-Cu effective?

Research by Pyo et al. (2007) showed efficacy at extremely low concentrations of 10^-12 to 10^-9 M in vitro. For topical formulations, concentrations of 0.5-1% are most commonly used, with a range of 0.3-2% in finished products. The optimal pH range for formulations is 5.0-7.0. Storage should be at 2-8 degrees Celsius in dark glass containers, and prepared solutions should be used within 30 days.